453 related articles for article (PubMed ID: 22367664)
21. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
[TBL] [Abstract][Full Text] [Related]
22. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
Wilens T; Pelham W; Stein M; Conners CK; Abikoff H; Atkins M; August G; Greenhill L; McBurnett K; Palumbo D; Swanson J; Wolraich M
J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):424-33. PubMed ID: 12649629
[TBL] [Abstract][Full Text] [Related]
23. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
[TBL] [Abstract][Full Text] [Related]
24. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.
Buitelaar JK; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; Casas M; van Oene JC; Schäuble B; Trott GE
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):554-60. PubMed ID: 21185347
[TBL] [Abstract][Full Text] [Related]
25. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
[TBL] [Abstract][Full Text] [Related]
27. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
Konstenius M; Jayaram-Lindström N; Beck O; Franck J
Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
[TBL] [Abstract][Full Text] [Related]
28. Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study.
Bron TI; Bijlenga D; Kasander MV; Spuijbroek AT; Beekman AT; Kooij JJ
Eur Neuropsychopharmacol; 2013 Jun; 23(6):542-54. PubMed ID: 22809706
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
Moungnoi P; Maipang P
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
[TBL] [Abstract][Full Text] [Related]
30. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
[TBL] [Abstract][Full Text] [Related]
31. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
32. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.
Levin FR; Evans SM; Brooks DJ; Kalbag AS; Garawi F; Nunes EV
Drug Alcohol Depend; 2006 Feb; 81(2):137-48. PubMed ID: 16102908
[TBL] [Abstract][Full Text] [Related]
33. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS
Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
McGough JJ; Wigal SB; Abikoff H; Turnbow JM; Posner K; Moon E
J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
[TBL] [Abstract][Full Text] [Related]
35. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
36. Naturalistic long-term use of methylphenidate in bipolar disorder.
Lydon E; El-Mallakh RS
J Clin Psychopharmacol; 2006 Oct; 26(5):516-8. PubMed ID: 16974196
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.
Adler LA; Orman C; Starr HL; Silber S; Palumbo J; Cooper K; Berwaerts J; Harrison DD
J Clin Psychopharmacol; 2011 Feb; 31(1):108-14. PubMed ID: 21192153
[TBL] [Abstract][Full Text] [Related]
38. Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey.
Lensing MB; Zeiner P; Sandvik L; Opjordsmoen S
J Clin Psychiatry; 2013 Jan; 74(1):e87-93. PubMed ID: 23419235
[TBL] [Abstract][Full Text] [Related]
39. Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Moore M; Burket R; Merkel RL; Mikami AY; Kovatchev B
J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):1-10. PubMed ID: 18294083
[TBL] [Abstract][Full Text] [Related]
40. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder.
Findling RL; Katic A; Rubin R; Moon E; Civil R; Li Y
J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):365-75. PubMed ID: 20973707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
